- World Pharma News Home » Clinical Trials » Data from one-year liraglutide phase 3 study published in The Lancet
(a free service delivered by FeedBurner)
Data from a 52-week phase 3 study (LEADâ„¢ 3) of liraglutide, a once-daily human GLP-1 analogue, were published by The Lancet. The study showed that liraglutide, when taken alone, produces statistically significant and sustained improvements in blood sugar control in patients with early type 2 diabetes, as compared with glimepiride, a widely used oral antidiabetic drug. Moreover, the treatment with liraglutide leads to weight loss, reduced systolic blood pressure and lower rates of hypoglycaemia after 52 weeks of treatment.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments